Examining changes over time in CLL cell surface markers to identify cells at different stages
MRD studies in ALL and AML
Venetoclax in combination with ibrutinib: can it control CLL?
Neomorphic mutations driving hematological cancers
How new drugs may change the standard of care for CLL